Concord Biotech Ltd (CONCORDBIO) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Concord Biotech reported steady growth in revenue and profitability for Q4 FY25 and the full fiscal year.
- Q4 FY25 revenue grew by 35% to INR 430 crores, while full-year revenue reached INR 1,200 crores, an 18% increase.
- Profit after tax (PAT) for FY25 was INR 372 crores, a 21% YoY growth.
- Strategic investments were made in Palvella Therapeutics and Clean Max, aligning with long-term growth and sustainability goals.
- Key regulatory approvals and successful commissioning of the injectable facility at Valthera marked significant milestones.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.